During Thursday’s trade, following is the summary for healthcare sector:
- INVITAE CORP (NYSE:NVTA), was the top gainer of the healthcare sector for the last trading session, and added 6.56% to the share.
- Unilife Corporation (NASDAQ:UNIS), was among the top loser of the sector, losing -6.17% from the share, and was settled at $4.26.
- Pfizer Inc. (NYSE:PFE) lately hits new 52-week high of $34.97, and was settled at $34.87.
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) lately hits new 52-week low of $6.68, and was settled at $6.95.
- ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), was the most volatile stock, and it remained 8.04% volatile for the week and 10.79% for the month.
- Pfizer Inc. (NYSE:PFE) , was the most active stock for the session, and gained volume of 43.66M.
- Curis, Inc. (NASDAQ:CRIS), will release their earning report, before the market close today.
Insights about some real losers from healthcare sector segment, amid Thursday’s exchange are depicted underneath:
Unilife Corporation (NASDAQ:UNIS), dipped -6.17% to close at $4.26, following the news release that Unilife Corporation (NASDAQ:UNIS), recently declared its financial results for the quarter ended December 31, 2014.
Key Features of Recent Financial Highlights:
- $7.3 million in cash receipts from customers in 2Q FY15,
- Quarterly proceed of $5.4 million, up 50% contrast to preceding year quarter,
- Deferred proceed of $17.1 million as of the end of 2Q FY15,
- Accomplished a U.S. public offering of ordinary stock, bringing net proceeds to Unilife of $44.7 million in February 2015.
Unilife Corporation (NASDAQ:UNIS), is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife’s broad portfolio of proprietary technologies comprises prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems.
Shares of Cigna Corp. (NYSE:CI), dropped -0.08% and closed at $114.98, hitting new 52-week high of $116.00, as part of its focus on Senior Care, the Cigna Foundation recently declared grants totaling $60,000 to be divided among three Nashville-based non-profits to assist area seniors enjoy healthier, more secure lives. The YMCA of Middle Tennessee, FiftyForward, and Bethlehem Centers of Nashville each received a $20,000 grant to aid and develop important senior-specific health programs.
Cigna Corp. (NYSE:CI), founded in 1962, is a private foundation funded by contributions from Cigna Corporation (CI) and its auxiliaries. The Cigna Foundation supports organizations sharing its commitment to enhancing the health of individuals and families, and the well-being of their communities, with a special focus on those communities where Cigna employees live and work.
Acorda Therapeutics, Inc. (NASDAQ:ACOR), dropped -0.65% to close at $36.65, as Acorda Therapeutics, Inc. (NASDAQ:ACOR), declared its financial results for the fourth quarter and full year ended December 31, 2014. The Company stated GAAP net revenue of $0.3 million for the quarter ended December 31, 2014, or $0.01 per diluted share. GAAP net revenue in the same quarter of 2013 was $6.2 million, or $0.15 per diluted share. For the full year ended December 31, 2014, the Company stated GAAP net revenue of $17.7 million, or $0.42 per diluted share. GAAP net revenue for the full year 2013 was $16.4 million, or $0.39 per diluted share.
Acorda Therapeutics, Inc. (NASDAQ:ACOR), is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda markets three FDA-approved therapies, counting AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS), as demonstrated by an raise in walking speed.
Shares of the Atara Biotherapeutics, Inc. (NASDAQ:ATRA), declined -2.43% & closed at $18.10, soon after Atara Biotherapeutics, Inc. (ATRA), declared the pricing of its underwritten public offering of 3,638,333 shares of its ordinary stock at a public offering price of $18.00 per share. In addition, Atara Bio has granted the underwriters a 30-day option to purchase up to an additional 545,749 shares of ordinary stock at the public offering price. The offering is predictable to close on February 18, 2015, subject to customary closing conditions.
Goldman, Sachs & Co. and Citigroup Global Markets Inc. are acting as joint book-running managers for the projected offering. Jefferies LLC is acting as co-manager.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), is a biopharmaceutical development company focusing on innovative therapies for patients with debilitating diseases. Atara Bio’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications.
Celgene Corporation (NASDAQ:CELG), dwindled -2.25% to close at $115.72, soon after Celgene International Sàrl, a wholly owned partner of Celgene Corporation (NASDAQ:CELG), declared that ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles; nab-paclitaxel), in combination with gemcitabine, has now received a positive recommendation for the treatment of metastatic pancreatic cancer by the Scottish Medicines Consortium (SMC) within the National Health Service Scotland. The decision follows the recent NHS England declaration to defer their review of ABRAXANE® for metastatic pancreatic cancer, allowing the treatment to remain on the National Cancer Drugs Fund (NCDF) list until a final decision is made.
Celgene Corporation (NASDAQ:CELG), headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
